Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**SASPject PT3** is an investigational intravenous antibacterial agent developed by Phico Therapeutics using the proprietary SASPject platform, which employs engineered bacteriophages to deliver a gene encoding small acid-soluble spore proteins (SASPs) specifically into *Pseudomonas aeruginosa* bacteria. The SASPs bind to and inactivate bacterial DNA regardless of sequence, preventing metabolism and reproduction while minimizing resistance development and sparing non-target bacteria. It targets serious hospital-acquired infections such as ventilator-associated pneumonia, urinary tract infections, bloodstream infections, and wound infections caused by multidrug-resistant *P. aeruginosa*, a WHO priority pathogen.[1][3][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SASPject PT3.